The FDA approved Gvoke, a ready-to-use glucagon product, for the treatment of severe hypoglycemia in 2019. The format is potentially more convenient than traditional glucagon kits from the likes ...

ACCP is a non-profit association providing accredited Continuing Education, publications and career-enhancing opportunities to clinical pharmacology healthcare professionals. We sell different ...

Liraglutide, a GLP-1 receptor agonist, has been shown to effectively lower glucagon levels and promote ... are expected to be improved through the use of combination therapy and personalized ...

Through this important partnership, we can save lives by ensuring individuals with diabetes who are treated with insulin have access to glucagon, preferably a ready-to-use formulation, so they can ...

With 62% of patients using glucagon-like peptide-1 (GLP-1) getting aesthetic treatment following a healthcare professional recommendation 1, there is a clear need for guidance on how to treat this ...

Recent research highlights a trend of high discontinuation rates among patients using glucagon-like peptide-1 receptor agonists for Type 2 diabetes and weight loss. A large cohort study examining ...

Pancreatic neuroendocrine tumors and liver cancer can hijack the body’s metabolic processes, using glucagon to increase glucose production and fuel their growth. In advanced liver cancer ...

Glucagon prescriptions for severe hypoglycemia ... This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Pancreatic neuroendocrine tumours and liver cancer can hijack the body's metabolic processes, using glucagon to increase glucose production and fuel their growth. In advanced liver cancer ...